{{drugbox
| Verifiedfields = changed
| verifiedrevid = 460765928
| IUPAC_name = (+)-(''S'')-''N''-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine
| image = Duloxetine.svg
| image2 = Duloxetine-3D-ball-model.png

<!--Clinical data-->
| tradename = Cymbalta
| Drugs.com = {{drugs.com|monograph|duloxetine}}
| MedlinePlus = a604030
| licence_EU = Ariclaim
| licence_US = duloxetine
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability = ~ 50% (32% to 80%)
| protein_bound = ~ 95%
| metabolism = 肝脏, 两种[[P450|P450]]酶, [[CYP2D6|CYP2D6]] 和[[CYP1A2|CYP1A2]]
| elimination_half-life = 12.1 小时
| excretion = 70% 尿液, 20% 粪便

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 116539-59-4
| CAS_number_comment = free base
| CAS_number2 = 136434-34-9
| CAS_number2_comment = [[盐酸盐|盐酸盐]]
| ATC_prefix = N06
| ATC_suffix = AX21
| PubChem = 60835
| IUPHAR_ligand = 202
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB00476
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 54822
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = O5TNM5N07U
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07880
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 36795
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1175
| PDB_ligand = 29E

<!--Chemical data-->
| C=18 | H=19 | N=1 | O=1 | S=1
| molecular_weight = 297.41456 g/mol
| smiles = CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
| InChI = 1/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
| InChIKey = ZEUITGRIYCTCEM-KRWDZBQOBW
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZEUITGRIYCTCEM-KRWDZBQOSA-N
}}

'''度洛西汀（{{lang-en|Duloxetine}}）'''，商品名为'''欣百达'''、'''奥思平'''，是一种[[5-羟色胺和去甲肾上腺素再摄取抑制剂|5-羟色胺和去甲肾上腺素再摄取抑制剂]]（SNRI），由[[礼来|礼来]]研发。度洛西汀常用来治疗[[重性抑郁障碍|重性抑郁障碍]]、[[广泛性焦虑症|广泛性焦虑症]]、[[纤维肌痛|纤维肌痛]]、各种[[躯体不适|躯体不适]]。<ref name=AHFS2015>{{cite web | title = Duloxetine | work = Monograph | url = http://www.drugs.com/monograph/duloxetine.html | publisher = The American Society of Health-System Pharmacists | accessdate = 2015-02-26 | archive-date = 2022-06-14 | archive-url = https://web.archive.org/web/20220614094726/https://www.drugs.com/monograph/duloxetine.html }}</ref><ref>{{NICE|96|Neuropathic pain - pharmacological management|2010}}</ref><ref>{{cite journal | author=Bril V, England J, Franklin GM | title=Evidence-based guideline: Treatment of painful diabetic neuropathy | journal=Neurology | year=2011 | volume=Online | pages= 1758–65| doi=10.1212/WNL.0b013e3182166ebe | pmid=21482920 | issue=20 | pmc=3100130| author2=and others | displayauthors=1 }}</ref>度洛西汀常作为治疗躯体化障碍的首选药物。

==引用==
{{reflist}}

{{Antidepressants}}
{{ADHD_pharmacotherapies}}
[[Category:抗抑郁药物|Category:抗抑郁药物]]
[[Category:萘酚醚|Category:萘酚醚]]